Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin, Trastuzumab, and Tislelizumab in Advanced Gastric/GEJ Adenocarcinoma
NCT07315750Phase 3Recruiting
- Sponsor
- RemeGen
- Start
- Jan 2026
- Primary completion
- Jun 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of disitamab vedotin in Gastric carcinoma (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by RemeGen. Primary endpoint: Progression-Free Survival (assessed by the BIRC) at 24 months. Started Jan 2026; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
Gastric carcinoma (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07315750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07315750.